A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Baricitinib (Primary)
- Indications Primary biliary cirrhosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Eli Lilly
- 24 Jan 2019 Planned initiation date changed from 31 Jan 2019 to 1 Feb 2019.
- 03 Jan 2019 Planned initiation date changed from 15 Dec 2018 to 31 Jan 2019.
- 22 Nov 2018 New trial record